AIOSYN
Aiosyn, a software company that develops AI-powered pathology software, has launched its first product that assists digital pathology labs across research, diagnostics and pharma to improve their quality control (QC) process. AiosynQC is an AI-powered algorithm that automatically scans for the most common artifacts that occur during the heterogeneous pre-analytical process.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005006/en/
Out-of-focus regions of an H&E stained slide image, blurry and difficult to read, are identified and highlighted with Aiosyn's automated quality control powered by AI. (Photo: Business Wire)
The algorithm of AiosynQC is trained on hematoxylin and eosin (H&E) stained slides. The product helps labs to ensure that only high-quality images are used by pathologists, technicians, and researchers. It can flag cases before presentation to a pathologist, thereby improving the efficiency of the digital pathology workflow by reducing the time that is currently used to manually check for artifacts in whole slide images.
AiosynQC is a modular and flexible software offered as a service solution that can be integrated into existing digital pathology software and deployed through the cloud or on-premise installation. The automated QC is the first product in Aiosyn’s workflow solutions suite. It will be part of a portfolio of deep learning algorithms currently in development for different pathologies for which there is a clear need to improve diagnostic precision and quality.
“AiosynQC will be an important foundational layer and we believe that AI-powered workflow solutions are the entry point for the use and adoption of computational pathology algorithms” according to Patrick de Boer, CEO of Aiosyn.
More information about AiosynQC can be found here.
About Aiosyn
Aiosyn is a Dutch medical software company that develops AI-powered pathology solutions that will be integrated into standard pathology workflows. The Aiosyn team has been built upon 20+ years of research experience in the field of pathology and is rooted into the pathology practice. More about Aiosyn can be found here.
AiosynQC
AiosynQC can only be used in the European Union and the United Kingdom. In the EU and the UK, AiosynQC is not considered a medical device under European IVDR and UK MDR 2002 legislation, respectively. AiosynQC is not intended to be used as an accessory to, nor is it necessary to be used in combination with, any AI or other medical devices to specifically enable them to meet their intended purpose or directly assist in their functionality.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005006/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TwentyTwo Real Estate and Farallon Capital Complete €761 Million Investment in Isemia, a €1.2bn Healthcare Real Estate Company Created With emeis14.1.2026 18:30:00 CET | Press release
TwentyTwo Real Estate, an independent European real estate investment and management firm, announces the completion, alongside Farallon Capital, of a €761 million investment that led to the creation of Isemia (www.isemiabyemeis.com), a leading healthcare real estate company holding a €1.2 billion portfolio of assets operated by emeis. The transaction represents a significant milestone in TwentyTwo Real Estate’s long-term investment strategy focused on healthcare and operational living real estate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114262830/en/ Fachklinik Schömberg Isemia comprises 68 high-quality assets across France, Germany and Spain, with a balanced mix of nursing homes (48%) and clinics (52%). The portfolio benefits from strong fundamentals and resilient operating performance. All properties will continue to be operated by emeis under long-term lease agreements, ensuring continuity of care for residents
AI’s Water Demand to Surge Nearly 130% by 2050 – New Research Shows How to Build a Water-Secure AI Economy14.1.2026 16:00:00 CET | Press release
Analysis finds AI could add 30 trillion liters of annual water demand, but targeted reuse and digital infrastructure investments can substantially offset demand and protect communities The rapid global expansion of artificial intelligence is set to drive a 129% increase in water demand across the AI value chain by 2050, according to new research by Xylem (NYSE: XYL) and Global Water Intelligence (GWI). Watering the New Economy: Managing the Impacts of the AI Revolution provides the most comprehensive assessment to date of how AI is reshaping global water use. It also highlights practical ways to meet that demand while strengthening water security for communities. Spending on AI is forecast to approach $2 trillion in 2026,1 accelerating infrastructure build-out worldwide. By the middle of the century, this expansion is projected to add 30 trillion liters of water demand, annually, fueled by a surge in power generation (~54% of the increase), semiconductor fabrication (~42%), and data ce
ACCELQ Crowned Leader and Customer Favorite in The Forrester Wave™ for Autonomous Testing Platforms14.1.2026 16:00:00 CET | Press release
Agentic Test Automation Pioneer Caps Record-Breaking Year of Growth and "AI-Based Engineering Solution of the Year" Honors Forrester has named ACCELQ a Leader in The Forrester Wave™: Autonomous Testing Platforms, Q4 2025. This marks the third consecutive Wave in which ACCELQ has been recognized as a Leader. Notably, this evaluation placed strong emphasis on generative AI innovation and real-world customer adoption. ACCELQ received the highest scores for both capabilities and vision and was the only platform to be recognized as a Customer Favorite, earning a "double halo" for exceptional customer endorsement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113112861/en/ ACCELQ recognized as a Leader and Customer Favorite in The Forrester Wave™️: Autonomous Testing Platforms, Q4 2025, validating its agentic, GenAI-embedded testing vision. According to the Forrester report, ACCELQ received the highest score among all evaluate
Primient to Acquire Full Ownership of Primient Covation, LLC14.1.2026 16:00:00 CET | Press release
Primient, a global leader in biomanufacturing, announced today it has agreed to purchase the remaining ownership interest in Primient Covation, LLC (“Primient Covation”), establishing Primient as the sole owner of the company and marking an exciting new chapter in Primient’s growth in the bioeconomy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114344080/en/ This acquisition is the next step of Primient’s strategy to strengthen Primient’s leadership position in biomanufacturing and builds upon recent announcements, including Primient’s partnership with Sustainea and the creation of the iPROOF venture. Primient Covation stands as a leading force in the U.S. biomanufacturing sector, distinguished by its broad range of biomanufacturing and fermentation expertise. The company was founded in 2000 to supply a variety of end markets, including cosmetics and personal care, textiles, fashion, coatings, functional fluids, and oth
BitGo Holdings annoncerer lancering af børsintroduktion14.1.2026 15:53:00 CET | Pressemeddelelse
BitGo Holdings, Inc. ("BitGo"), som er en virksomhed inden for digital infrastruktur til aktiver, annoncerede i dag lanceringen af sin børsintroduktion af 11.821.595 aktier af klasse A-stamaktier i henhold til en registreringserklæring på formular S-1, der er indsendt til det amerikanske finanstilsyn, U.S. Securities and Exchange Commission (kendt som "SEC"). Udbuddet omfatter 11.000.000 aktier af klasse A-stamaktier udbudt af BitGo samt 821.595 aktier af klasse A-stamaktier udbudt af visse eksisterende aktionærer i BitGo. BitGo vil ikke modtage noget provenu fra salget af aktier fra de sælgende aktionærer i forbindelse med udbuddet. I forbindelse med udbuddet har BitGo til hensigt at give konsortiet af garantibanker en 30-dages option til at købe op til yderligere 1.770.000 aktier af klasse A-stamaktier. Den forventede introduktionskurs i forbindelse med børsnoteringen vil ligge mellem 15 og 17 USD pr. aktie. BitGo har ansøgt om at få sine klasse A-stamaktier optaget til handel på New
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom